Hertz DL, Joerger M, Bang YJ, Mathijssen RH, Zhou C, Zhang L, Gandara D, Stahl M, Monk BJ, Jaehde U, Beumer JH. Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations. Eur J Cancer. 2024-05-01;202114024. doi: 10.1016/j.ejca.2024.114024. nihFormattedCitation: Hertz DL, Joerger M, Bang YJ, Mathijssen RH, Zhou C, Zhang L, Gandara D, Stahl M, Monk BJ, Jaehde U, Beumer JH. Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations. Eur J Cancer. 2024;202:114024.. PubMed PMID: 38513383.
Abdullah KG. Classifying glioma via liquid biopsy--progress towards an unmet clinical need. Clin Cancer Res. 2024-04-23; doi: 10.1158/1078-0432.CCR-24-0423. nihFormattedCitation: Abdullah KG. Classifying glioma via liquid biopsy--progress towards an unmet clinical need. Clin Cancer Res. 2024;.. PubMed PMID: 38652677.
Geyer CE Jr, Blum JL, Yothers G, Asmar L, Flynn PJ, Robert NJ, Hopkins JO, O'Shaughnessy JA, Rastogi P, Puhalla SL, Hilton CJ, Dang CT, Gómez HL, Vukelja SJ, Lyss AP, Paul D, Brufsky AM, Colangelo LH, Swain SM, Mamounas EP, Wolmark N. Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]). J Clin Oncol. 2024-04-20;JCO2301428. doi: 10.1200/JCO.23.01428. nihFormattedCitation: Geyer CE Jr, Blum JL, Yothers G, Asmar L, Flynn PJ, Robert NJ, Hopkins JO, O'Shaughnessy JA, Rastogi P, Puhalla SL, Hilton CJ, Dang CT, Gómez HL, Vukelja SJ, Lyss AP, Paul D, Brufsky AM, Colangelo LH, Swain SM, Mamounas EP, Wolmark N. Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]). J Clin Oncol. 2024;:JCO2301428.. PubMed PMID: 38335467.
Butrovich MA, Qin J, Xue X, Ivy SP, Nolin TD, Beumer JH. Impact of the 2021 CKD-EPI equation on anticancer pharmacotherapy in black and non-black cancer patients. Cancer Lett. 2024-04-01;216679. doi: 10.1016/j.canlet.2024.216679. nihFormattedCitation: Butrovich MA, Qin J, Xue X, Ivy SP, Nolin TD, Beumer JH. Impact of the 2021 CKD-EPI equation on anticancer pharmacotherapy in black and non-black cancer patients. Cancer Lett. 2024;:216679. PMCID: PMC10939791.. PubMed PMID: 38307411; PMCID: PMC10939791.
Appleman LJ, Kim SE, Harris WB, Pal SK, Pins MR, Kolesar J, Agarwal N, Parikh RA, Vaena DA, Ryan CW, Hashmi M, Costello BA, Cella D, Dutcher JP, DiPaola RS, Haas NB, Wagner LI, Carducci MA. Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810. J Clin Oncol. 2024-03-26;JCO2301544. doi: 10.1200/JCO.23.01544. nihFormattedCitation: Appleman LJ, Kim SE, Harris WB, Pal SK, Pins MR, Kolesar J, Agarwal N, Parikh RA, Vaena DA, Ryan CW, Hashmi M, Costello BA, Cella D, Dutcher JP, DiPaola RS, Haas NB, Wagner LI, Carducci MA. Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810. J Clin Oncol. 2024;:JCO2301544.. PubMed PMID: 38531002.
Rastogi P, O'Shaughnessy J, Martin M, Boyle F, Cortes J, Rugo HS, Goetz MP, Hamilton EP, Huang CS, Senkus E, Tryakin A, Cicin I, Testa L, Neven P, Huober J, Shao Z, Wei R, André V, Munoz M, San Antonio B, Shahir A, Harbeck N, Johnston S. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Ou J Clin Oncol. 2024-03-20;JCO2301994. doi: 10.1200/JCO.23.01994. nihFormattedCitation: Rastogi P, O'Shaughnessy J, Martin M, Boyle F, Cortes J, Rugo HS, Goetz MP, Hamilton EP, Huang CS, Senkus E, Tryakin A, Cicin I, Testa L, Neven P, Huober J, Shao Z, Wei R, André V, Munoz M, San Antonio B, Shahir A, Harbeck N, Johnston S. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Ou J Clin Oncol. 2024;:JCO2301994. PMCID: PMC10950161.. PubMed PMID: 38194616; PMCID: PMC10950161.
You KL, Sereika SM, Bender CM, Hamilton JB, Mazanec SR, Brufsky A, Rosenzweig MQ. Health-related quality of life over chemotherapy course among individuals with early-stage breast cancer: the association of social determinants of health and neighborhood socioeconomic disadvantage. Support Care Cancer. 2024-03-12;32(4):224. doi: 10.1007/s00520-024-08429-y. nihFormattedCitation: You KL, Sereika SM, Bender CM, Hamilton JB, Mazanec SR, Brufsky A, Rosenzweig MQ. Health-related quality of life over chemotherapy course among individuals with early-stage breast cancer: the association of social determinants of health and neighborhood socioeconomic disadvantage. Support Care Cancer. 2024;32(4):224.. PubMed PMID: 38472437.
Chen Y, Chen CY, Huang H, Luo Z, Mu Y, Li S, Li S. Knocking down of Xkr8 enhances chemotherapy efficacy through modulating tumor immune microenvironment. J Control Release. 2024-03-10; doi: 10.1016/j.jconrel.2024.03.011. nihFormattedCitation: Chen Y, Chen CY, Huang H, Luo Z, Mu Y, Li S, Li S. Knocking down of Xkr8 enhances chemotherapy efficacy through modulating tumor immune microenvironment. J Control Release. 2024;.. PubMed PMID: 38471639.
Im A, Quann K, Agha M, Raptis A, Redner RL, Hou JZ, Farah R, Dorritie KA, Sehgal AR, Normolle D, Bovbjerg DH, Aggarwal N, Herman J, Lontos K, Boyiadzis M. Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients. Am J Hematol. 2024-03-01; doi: 10.1002/ajh.27212. nihFormattedCitation: Im A, Quann K, Agha M, Raptis A, Redner RL, Hou JZ, Farah R, Dorritie KA, Sehgal AR, Normolle D, Bovbjerg DH, Aggarwal N, Herman J, Lontos K, Boyiadzis M. Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients. Am J Hematol. 2024;.. PubMed PMID: 38258329.
Xu P, Xi Y, Kim JW, Zhu J, Zhang M, Xu M, Ren S, Yang D, Ma X, Xie W. Sulfation of chondroitin and bile acids converges to antagonize Wnt/β-catenin signaling and inhibit APC deficiency-induced gut tumorigenesis. Acta Pharm Sin B. 2024-03-01;14(3):1241-1256. doi: 10.1016/j.apsb.2023.12.006. nihFormattedCitation: Xu P, Xi Y, Kim JW, Zhu J, Zhang M, Xu M, Ren S, Yang D, Ma X, Xie W. Sulfation of chondroitin and bile acids converges to antagonize Wnt/β-catenin signaling and inhibit APC deficiency-induced gut tumorigenesis. Acta Pharm Sin B. 2024;14(3):1241-1256. PMCID: PMC10935170.. PubMed PMID: 38487006; PMCID: PMC10935170.
Chao Y, Chen Y, Zheng W, Demanelis K, Liu Y, Connelly JA, Wang H, Li S, Wang QJ. Synthetic lethal combination of CHK1 and WEE1 inhibition for treatment of castration-resistant prostate cancer. Oncogene. 2024-03-01; doi: 10.1038/s41388-024-02939-z. nihFormattedCitation: Chao Y, Chen Y, Zheng W, Demanelis K, Liu Y, Connelly JA, Wang H, Li S, Wang QJ. Synthetic lethal combination of CHK1 and WEE1 inhibition for treatment of castration-resistant prostate cancer. Oncogene. 2024;.. PubMed PMID: 38273024.
Mamounas EP, Bandos H, Rastogi P, Zhang Y, Treuner K, Lucas PC, Geyer CE, Fehrenbacher L, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil S, Paik S, Swain SM, Sgroi DC, Schnabel CA, Wolmark N. Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial. Clin Cancer Res. 2024-02-20; doi: 10.1158/1078-0432.CCR-23-1977. nihFormattedCitation: Mamounas EP, Bandos H, Rastogi P, Zhang Y, Treuner K, Lucas PC, Geyer CE, Fehrenbacher L, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil S, Paik S, Swain SM, Sgroi DC, Schnabel CA, Wolmark N. Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial. Clin Cancer Res. 2024;.. PubMed PMID: 38376912.
Saeed A, Park R, Pathak H, Al-Bzour AN, Dai J, Phadnis M, Al-Rajabi R, Kasi A, Baranda J, Sun W, Williamson S, Chiu YC, Osmanbeyoglu HU, Madan R, Abushukair H, Mulvaney K, Godwin AK, Saeed A. Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort. Nat Commun. 2024-02-20;15(1):1533. doi: 10.1038/s41467-024-45960-2. nihFormattedCitation: Saeed A, Park R, Pathak H, Al-Bzour AN, Dai J, Phadnis M, Al-Rajabi R, Kasi A, Baranda J, Sun W, Williamson S, Chiu YC, Osmanbeyoglu HU, Madan R, Abushukair H, Mulvaney K, Godwin AK, Saeed A. Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort. Nat Commun. 2024;15(1):1533. PMCID: PMC10879200.. PubMed PMID: 38378868; PMCID: PMC10879200.
Owonikoko TK. SCLC Classification by Platinum Sensitivity in the Era of Immunotherapy: Mere Relic or a Valuable Treasure to Keep? J Thorac Oncol. 2024-02-01;19(2):193-195. doi: 10.1016/j.jtho.2023.11.022. nihFormattedCitation: Owonikoko TK. SCLC Classification by Platinum Sensitivity in the Era of Immunotherapy: Mere Relic or a Valuable Treasure to Keep? J Thorac Oncol. 2024;19(2):193-195.. PubMed PMID: 38325978.
Casillo SM, Gatesman TA, Chilukuri A, Varadharajan S, Johnson BJ, David Premkumar DR, Jane EP, Plute TJ, Koncar RF, Stanton AJ, Biagi-Junior CAO, Barber CS, Halbert ME, Golbourn BJ, Halligan K, Cruz AF, Mansi NM, Cheney A, Mullett SJ, Land CV, Perez JL, Myers MI, Agrawal N, Michel JJ, Chang YF, Vaske OM, MichaelRaj A, Lieberman FS, Felker J, Shiva S, Bertrand KC, Amankulor N, Hadjipanayis CG, Abdullah KG, Zinn PO, Friedlander RM, Abel TJ, Nazarian J, Venneti S, Filbin MG, Gelhaus SL, Mack SC, Pollack IF, Agnihotri S. An ERK5-PFKFB3 axis regulates glycolysis and represents a therapeutic vulnerability in pediatric diffuse midline glioma. Cell Rep. 2024-01-23;43(1):113557. doi: 10.1016/j.celrep.2023.113557. nihFormattedCitation: Casillo SM, Gatesman TA, Chilukuri A, Varadharajan S, Johnson BJ, David Premkumar DR, Jane EP, Plute TJ, Koncar RF, Stanton AJ, Biagi-Junior CAO, Barber CS, Halbert ME, Golbourn BJ, Halligan K, Cruz AF, Mansi NM, Cheney A, Mullett SJ, Land CV, Perez JL, Myers MI, Agrawal N, Michel JJ, Chang YF, Vaske OM, MichaelRaj A, Lieberman FS, Felker J, Shiva S, Bertrand KC, Amankulor N, Hadjipanayis CG, Abdullah KG, Zinn PO, Friedlander RM, Abel TJ, Nazarian J, Venneti S, Filbin MG, Gelhaus SL, Mack SC, Pollack IF, Agnihotri S. An ERK5-PFKFB3 axis regulates glycolysis and represents a therapeutic vulnerability in pediatric diffuse midline glioma. Cell Rep. 2024;43(1):113557.. PubMed PMID: 38113141.
Kelly WK, Danila DC, Lin CC, Lee JL, Matsubara N, Ward PJ, Armstrong AJ, Pook D, Kim M, Dorff TB, Fischer S, Lin YC, Horvath LG, Sumey C, Yang Z, Jurida G, Smith KM, Connarn JN, Penny HL, Stieglmaier J, Appleman LJ. Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. Cancer Discov. 2024-01-12;OF1-OF14. doi: 10.1158/2159-8290.CD-23-0964. nihFormattedCitation: Kelly WK, Danila DC, Lin CC, Lee JL, Matsubara N, Ward PJ, Armstrong AJ, Pook D, Kim M, Dorff TB, Fischer S, Lin YC, Horvath LG, Sumey C, Yang Z, Jurida G, Smith KM, Connarn JN, Penny HL, Stieglmaier J, Appleman LJ. Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. Cancer Discov. 2024;:OF1-OF14. PMCID: PMC10784743.. PubMed PMID: 37861461; PMCID: PMC10784743.
Beumer JH, Salamone SJ. Project Confirm: Accelerated Drug Approvals for CML-Letter. Clin Cancer Res. 2024-01-05;30(1):235-236. doi: 10.1158/1078-0432.CCR-23-2630. nihFormattedCitation: Beumer JH, Salamone SJ. Project Confirm: Accelerated Drug Approvals for CML-Letter. Clin Cancer Res. 2024;30(1):235-236. PMCID: PMC10783536.. PubMed PMID: 38178775; PMCID: PMC10783536.
Luo Z, Huang Y, Batra N, Chen Y, Huang H, Wang Y, Zhang Z, Li S, Chen CY, Wang Z, Sun J, Wang QJ, Yang D, Lu B, Conway JF, Li LY, Yu AM, Li S. Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy. Nat Commun. 2024-01-04;15(1):255. doi: 10.1038/s41467-023-44572-6. nihFormattedCitation: Luo Z, Huang Y, Batra N, Chen Y, Huang H, Wang Y, Zhang Z, Li S, Chen CY, Wang Z, Sun J, Wang QJ, Yang D, Lu B, Conway JF, Li LY, Yu AM, Li S. Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy. Nat Commun. 2024;15(1):255. PMCID: PMC10766965.. PubMed PMID: 38177179; PMCID: PMC10766965.
Jonasch E, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, Dror Michaelson M, Appleman LJ, Roy A, Perini RF, Liu Y, Choueiri TK. Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort. Eur J Cancer. 2024-01-01;196113434. doi: 10.1016/j.ejca.2023.113434. nihFormattedCitation: Jonasch E, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, Dror Michaelson M, Appleman LJ, Roy A, Perini RF, Liu Y, Choueiri TK. Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort. Eur J Cancer. 2024;196:113434.. PubMed PMID: 38008031.
Murthy P, Zenati MS, AlMasri SS, DeSilva A, Singhi AD, Paniccia A, Lee KK, Simmons RL, Bahary N, Lotze MT, Zureikat AH. Impact of Recombinant Granulocyte Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected Pancreatic Cancer. J Natl Compr Canc Netw. 2023-12-27;1-13. doi: 10.6004/jnccn.2023.7070. nihFormattedCitation: Murthy P, Zenati MS, AlMasri SS, DeSilva A, Singhi AD, Paniccia A, Lee KK, Simmons RL, Bahary N, Lotze MT, Zureikat AH. Impact of Recombinant Granulocyte Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected Pancreatic Cancer. J Natl Compr Canc Netw. 2023;:1-13.. PubMed PMID: 38150819.
Beard JP, Bressin RK, Markaj PL, Schmitz JC, Koide K. Synthesis and Conformational Analysis of FR901464-Based RNA Splicing Modulators and Their Synergism in Drug-Resistant Cancers. J Med Chem. 2023-11-09; doi: 10.1021/acs.jmedchem.3c00733. nihFormattedCitation: Beard JP, Bressin RK, Markaj PL, Schmitz JC, Koide K. Synthesis and Conformational Analysis of FR901464-Based RNA Splicing Modulators and Their Synergism in Drug-Resistant Cancers. J Med Chem. 2023;. PMCID: PMC10641826.. PubMed PMID: 37870431; PMCID: PMC10641826.
Mamounas EP, Bandos H, Rastogi P, Lembersky BC, Jeong JH, Geyer CE, Fehrenbacher L, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil SR, Wade JL, McCarron EC, Swain SM, Wolmark N. Ten-year Update: NRG Oncology/NSABP B-42 Randomized Trial: Extended Letrozole Therapy in Early-stage Breast Cancer. J Natl Cancer Inst. 2023-11-08; doi: 10.1093/jnci/djad078. nihFormattedCitation: Mamounas EP, Bandos H, Rastogi P, Lembersky BC, Jeong JH, Geyer CE, Fehrenbacher L, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil SR, Wade JL, McCarron EC, Swain SM, Wolmark N. Ten-year Update: NRG Oncology/NSABP B-42 Randomized Trial: Extended Letrozole Therapy in Early-stage Breast Cancer. J Natl Cancer Inst. 2023;. PMCID: PMC10637036.. PubMed PMID: 37184928; PMCID: PMC10637036.
Puthanmadhom Narayanan S, Ren D, Oesterreich S, Lee AV, Rosenzweig MQ, Brufsky AM. Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer. NPJ Breast Cancer. 2023-11-01;9(1):90. doi: 10.1038/s41523-023-00595-2. nihFormattedCitation: Puthanmadhom Narayanan S, Ren D, Oesterreich S, Lee AV, Rosenzweig MQ, Brufsky AM. Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer. NPJ Breast Cancer. 2023;9(1):90. PMCID: PMC10620133.. PubMed PMID: 37914742; PMCID: PMC10620133.
Xu P, Cai X, Guan X, Xie W. Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases. Pharmacol Ther. 2023-11-01;108540. doi: 10.1016/j.pharmthera.2023.108540. nihFormattedCitation: Xu P, Cai X, Guan X, Xie W. Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases. Pharmacol Ther. 2023;:108540. PMCID: PMC10842354.. PubMed PMID: 37777160; PMCID: PMC10842354.
Albright S, Cacace M, Tivon Y, Deiters A. Cell Surface Labeling and Detection of Protein Tyrosine Kinase 7 via Covalent Aptamers. J Am Chem Soc. 2023-08-02;145(30):16458-16463. doi: 10.1021/jacs.3c02752. nihFormattedCitation: Albright S, Cacace M, Tivon Y, Deiters A. Cell Surface Labeling and Detection of Protein Tyrosine Kinase 7 via Covalent Aptamers. J Am Chem Soc. 2023;145(30):16458-16463. PMCID: PMC10401710.. PubMed PMID: 37473438; PMCID: PMC10401710.
Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N. Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer. J Clin Oncol. 2023-07-10;41(20):3565-3575. doi: 10.1200/JCO.22.02570. nihFormattedCitation: Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N. Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer. J Clin Oncol. 2023;41(20):3565-3575.. PubMed PMID: 37406456.
Foldi J, Geyer CE Jr. Precision medicine for metastatic TNBC: the FUTURE is now. Cell Res. 2023-07-01;33(7):491-492. doi: 10.1038/s41422-023-00815-1. nihFormattedCitation: Foldi J, Geyer CE Jr. Precision medicine for metastatic TNBC: the FUTURE is now. Cell Res. 2023;33(7):491-492. PMCID: PMC10313756.. PubMed PMID: 37156878; PMCID: PMC10313756.
Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, Hummel HD, Borghaei H, Johnson ML, Steeghs N, Blackhall F, Dowlati A, Reguart N, Yoshida T, He K, Gadgeel SM, Felip E, Zhang Y, Pati A, Minocha M, Mukherjee S, Goldrick A, Nagorsen D, Hashemi Sadraei N, Owonikoko TK. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023-06-01;41(16):2893-2903. doi: 10.1200/JCO.22.02823. nihFormattedCitation: Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, Hummel HD, Borghaei H, Johnson ML, Steeghs N, Blackhall F, Dowlati A, Reguart N, Yoshida T, He K, Gadgeel SM, Felip E, Zhang Y, Pati A, Minocha M, Mukherjee S, Goldrick A, Nagorsen D, Hashemi Sadraei N, Owonikoko TK. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023;41(16):2893-2903. PMCID: PMC10414718.. PubMed PMID: 36689692; PMCID: PMC10414718.
Mascarella MA, Olonisakin TF, Rumde P, Vendra V, Nance MA, Kim S, Kubik MW, Sridharan SS, Ferris RL, Fenton MJ, Clayburgh DR, Ohr JP, Joyce SC, Sen M, Herman JG, Grandis JR, Zandberg DP, Duvvuri U. Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit. Clin Cancer Res. 2023-02-16;29(4):723-730. doi: 10.1158/1078-0432.CCR-22-1768. nihFormattedCitation: Mascarella MA, Olonisakin TF, Rumde P, Vendra V, Nance MA, Kim S, Kubik MW, Sridharan SS, Ferris RL, Fenton MJ, Clayburgh DR, Ohr JP, Joyce SC, Sen M, Herman JG, Grandis JR, Zandberg DP, Duvvuri U. Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit. Clin Cancer Res. 2023;29(4):723-730.. PubMed PMID: 36595540.
Chen Y, Huang Y, Li Q, Luo Z, Zhang Z, Huang H, Sun J, Zhang L, Sun R, Bain DJ, Conway JF, Lu B, Li S. Targeting Xkr8 via nanoparticle-mediated in situ co-delivery of siRNA and chemotherapy drugs for cancer immunochemotherapy. Nat Nanotechnol. 2023-02-01;18(2):193-204. doi: 10.1038/s41565-022-01266-2. nihFormattedCitation: Chen Y, Huang Y, Li Q, Luo Z, Zhang Z, Huang H, Sun J, Zhang L, Sun R, Bain DJ, Conway JF, Lu B, Li S. Targeting Xkr8 via nanoparticle-mediated in situ co-delivery of siRNA and chemotherapy drugs for cancer immunochemotherapy. Nat Nanotechnol. 2023;18(2):193-204. PMCID: PMC9974593.. PubMed PMID: 36424448; PMCID: PMC9974593.
Pizzoni A, Zhang X, Naim N, Altschuler DL. Soluble cyclase-mediated nuclear cAMP synthesis is sufficient for cell proliferation. Proc Natl Acad Sci U S A. 2023-01-24;120(4):e2208749120. doi: 10.1073/pnas.2208749120. nihFormattedCitation: Pizzoni A, Zhang X, Naim N, Altschuler DL. Soluble cyclase-mediated nuclear cAMP synthesis is sufficient for cell proliferation. Proc Natl Acad Sci U S A. 2023;120(4):e2208749120. PMCID: PMC9942871.. PubMed PMID: 36656863; PMCID: PMC9942871.
Hammad AY, Hodges JC, AlMasri S, Paniccia A, Lee KK, Bahary N, Singhi AD, Ellsworth SG, Aldakkak M, Evans DB, Tsai S, Zureikat A. Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy. JAMA Surg. 2023-01-01;158(1):55-62. doi: 10.1001/jamasurg.2022.5696. nihFormattedCitation: Hammad AY, Hodges JC, AlMasri S, Paniccia A, Lee KK, Bahary N, Singhi AD, Ellsworth SG, Aldakkak M, Evans DB, Tsai S, Zureikat A. Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy. JAMA Surg. 2023;158(1):55-62. PMCID: PMC9685551.. PubMed PMID: 36416848; PMCID: PMC9685551.
Zhang Y, Li J, Huang Y, Chen Y, Luo Z, Huang H, West RE 3rd, Nolin TD, Wang Z, Li S. Improved antitumor activity against prostate cancer via synergistic targeting of Myc and GFAT-1. Theranostics. 2023-01-01;13(2):578-595. doi: 10.7150/thno.76614. nihFormattedCitation: Zhang Y, Li J, Huang Y, Chen Y, Luo Z, Huang H, West RE 3rd, Nolin TD, Wang Z, Li S. Improved antitumor activity against prostate cancer via synergistic targeting of Myc and GFAT-1. Theranostics. 2023;13(2):578-595. PMCID: PMC9830436.. PubMed PMID: 36632215; PMCID: PMC9830436.
Emanuelson C, Ankenbruck N, Kumbhare R, Thomas M, Connelly C, Baktash Y, Randall G, Deiters A. Transcriptional Inhibition of MicroRNA miR-122 by Small Molecules Reduces Hepatitis C Virus Replication in Liver Cells. J Med Chem. 2022-12-22;65(24):16338-16352. doi: 10.1021/acs.jmedchem.2c01141. nihFormattedCitation: Emanuelson C, Ankenbruck N, Kumbhare R, Thomas M, Connelly C, Baktash Y, Randall G, Deiters A. Transcriptional Inhibition of MicroRNA miR-122 by Small Molecules Reduces Hepatitis C Virus Replication in Liver Cells. J Med Chem. 2022;65(24):16338-16352. PMCID: PMC9942140.. PubMed PMID: 36449366; PMCID: PMC9942140.
Beumer JH, Chu E, Salamone SJ. All Optimal Dosing Roads Lead to Therapeutic Drug Monitoring-Why Take the Slow Lane. JAMA Oncol. 2022-12-01;8(12):1733-1735. doi: 10.1001/jamaoncol.2022.4452. nihFormattedCitation: Beumer JH, Chu E, Salamone SJ. All Optimal Dosing Roads Lead to Therapeutic Drug Monitoring-Why Take the Slow Lane. JAMA Oncol. 2022;8(12):1733-1735. PMCID: PMC9772116.. PubMed PMID: 36264552; PMCID: PMC9772116.
Carleton N, McAuliffe PF. Are the chronological age cutoffs used in clinical oncology guidelines biologically meaningful? Nat Rev Clin Oncol. 2022-12-01;19(12):745-746. doi: 10.1038/s41571-022-00684-4. nihFormattedCitation: Carleton N, McAuliffe PF. Are the chronological age cutoffs used in clinical oncology guidelines biologically meaningful? Nat Rev Clin Oncol. 2022;19(12):745-746. PMCID: PMC9675711.. PubMed PMID: 36042383; PMCID: PMC9675711.
AlMasri S, Zenati M, Hammad A, Nassour I, Liu H, Hogg ME, Zeh HJ, Boone B, Bahary N, Singhi AD, Lee KK, Paniccia A, Zureikat AH. Adaptive Dynamic Therapy and Survivorship for Operable Pancreatic Cancer. JAMA Netw Open. 2022-06-01;5(6):e2218355. doi: 10.1001/jamanetworkopen.2022.18355. nihFormattedCitation: AlMasri S, Zenati M, Hammad A, Nassour I, Liu H, Hogg ME, Zeh HJ, Boone B, Bahary N, Singhi AD, Lee KK, Paniccia A, Zureikat AH. Adaptive Dynamic Therapy and Survivorship for Operable Pancreatic Cancer. JAMA Netw Open. 2022;5(6):e2218355. PMCID: PMC9227002.. PubMed PMID: 35737385; PMCID: PMC9227002.
AlMasri SS, Zenati MS, Dasyam A, Singhi AD, Lee KK, Bartlett DL, Slivka A, Mcgrath K, Chennat J, Fasanella KE, Khalid A, Brand RE, Sarkaria S, Das R, Hogg ME, Zeh HJ, Paniccia A, Zureikat AH. Significance of Uncinate Duct Dilatation in IPMNs: A New High-risk Criterion? Ann Surg. 2022-06-01;275(6):e789-e795. doi: 10.1097/SLA.0000000000004307. nihFormattedCitation: AlMasri SS, Zenati MS, Dasyam A, Singhi AD, Lee KK, Bartlett DL, Slivka A, Mcgrath K, Chennat J, Fasanella KE, Khalid A, Brand RE, Sarkaria S, Das R, Hogg ME, Zeh HJ, Paniccia A, Zureikat AH. Significance of Uncinate Duct Dilatation in IPMNs: A New High-risk Criterion? Ann Surg. 2022;275(6):e789-e795.. PubMed PMID: 33201115.
Vyas A, Gomez-Casal R, Cruz-Rangel S, Villanueva H, Sikora AG, Rajagopalan P, Basu D, Pacheco J, Hammond GRV, Kiselyov K, Duvvuri U. Lysosomal inhibition sensitizes TMEM16A-expressing cancer cells to chemotherapy. Proc Natl Acad Sci U S A. 2022-03-22;119(12):e2100670119. doi: 10.1073/pnas.2100670119. nihFormattedCitation: Vyas A, Gomez-Casal R, Cruz-Rangel S, Villanueva H, Sikora AG, Rajagopalan P, Basu D, Pacheco J, Hammond GRV, Kiselyov K, Duvvuri U. Lysosomal inhibition sensitizes TMEM16A-expressing cancer cells to chemotherapy. Proc Natl Acad Sci U S A. 2022;119(12):e2100670119. PMCID: PMC8944912.. PubMed PMID: 35286200; PMCID: PMC8944912.
Moharil P, Wan Z, Pardeshi A, Li J, Huang H, Luo Z, Rathod S, Zhang Z, Chen Y, Zhang B, Fernandez CA, Sun J, Li S. Engineering a folic acid-decorated ultrasmall gemcitabine nanocarrier for breast cancer therapy: Dual targeting of tumor cells and tumor-associated macrophages. Acta Pharm Sin B. 2022-03-01;12(3):1148-1162. doi: 10.1016/j.apsb.2021.09.024. nihFormattedCitation: Moharil P, Wan Z, Pardeshi A, Li J, Huang H, Luo Z, Rathod S, Zhang Z, Chen Y, Zhang B, Fernandez CA, Sun J, Li S. Engineering a folic acid-decorated ultrasmall gemcitabine nanocarrier for breast cancer therapy: Dual targeting of tumor cells and tumor-associated macrophages. Acta Pharm Sin B. 2022;12(3):1148-1162. PMCID: PMC9072252.. PubMed PMID: 35530140; PMCID: PMC9072252.
Diamantopoulos LN, Appleman LJ. HLA-A*03 and response to immune checkpoint blockade in patients with cancer. Lancet Oncol. 2022-03-01;23(3):e99. doi: 10.1016/S1470-2045(22)00086-9. nihFormattedCitation: Diamantopoulos LN, Appleman LJ. HLA-A*03 and response to immune checkpoint blockade in patients with cancer. Lancet Oncol. 2022;23(3):e99.. PubMed PMID: 35240100.
Wan Z, Sun R, Liu YW, Li S, Sun J, Li J, Zhu J, Moharil P, Zhang B, Ren P, Ren G, Zhang M, Ma X, Dai S, Yang D, Lu B, Li S. Targeting metabotropic glutamate receptor 4 for cancer immunotherapy. Sci Adv. 2021-12-10;7(50):eabj4226. doi: 10.1126/sciadv.abj4226. nihFormattedCitation: Wan Z, Sun R, Liu YW, Li S, Sun J, Li J, Zhu J, Moharil P, Zhang B, Ren P, Ren G, Zhang M, Ma X, Dai S, Yang D, Lu B, Li S. Targeting metabotropic glutamate receptor 4 for cancer immunotherapy. Sci Adv. 2021;7(50):eabj4226. PMCID: PMC8664261.. PubMed PMID: 34890233; PMCID: PMC8664261.
Vyas A, Harbison RA, Faden DL, Kubik M, Palmer D, Zhang Q, Osmanbeyoglu HU, Kiselyov K, Méndez E, Duvvuri U. Recurrent Human Papillomavirus-Related Head and Neck Cancer Undergoes Metabolic Reprogramming and Is Driven by Oxidative Phosphorylation. Clin Cancer Res. 2021-11-15;27(22):6250-6264. doi: 10.1158/1078-0432.CCR-20-4789. nihFormattedCitation: Vyas A, Harbison RA, Faden DL, Kubik M, Palmer D, Zhang Q, Osmanbeyoglu HU, Kiselyov K, Méndez E, Duvvuri U. Recurrent Human Papillomavirus-Related Head and Neck Cancer Undergoes Metabolic Reprogramming and Is Driven by Oxidative Phosphorylation. Clin Cancer Res. 2021;27(22):6250-6264. PMCID: PMC8611487.. PubMed PMID: 34407971; PMCID: PMC8611487.
Gomez Marti JL, Nasrazadani A, Brufsky AM. Ovarian function suppression as a potential mechanism of chemotherapy. EBioMedicine. 2021-08-01;70103489. doi: 10.1016/j.ebiom.2021.103489. nihFormattedCitation: Gomez Marti JL, Nasrazadani A, Brufsky AM. Ovarian function suppression as a potential mechanism of chemotherapy. EBioMedicine. 2021;70:103489. PMCID: PMC8318981.. PubMed PMID: 34280778; PMCID: PMC8318981.
Cobleigh MA, Anderson SJ, Siziopikou KP, Arthur DW, Rabinovitch R, Julian TB, Parda DS, Seaward SA, Carter DL, Lyons JA, Dillmon MS, Magrinat GC, Kavadi VS, Zibelli AM, Tiriveedhi L, Hill ML, Melnik MK, Beriwal S, Mamounas EP, Wolmark N. Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial. J Clin Oncol. 2021-07-20;39(21):2367-2374. doi: 10.1200/JCO.20.02824. nihFormattedCitation: Cobleigh MA, Anderson SJ, Siziopikou KP, Arthur DW, Rabinovitch R, Julian TB, Parda DS, Seaward SA, Carter DL, Lyons JA, Dillmon MS, Magrinat GC, Kavadi VS, Zibelli AM, Tiriveedhi L, Hill ML, Melnik MK, Beriwal S, Mamounas EP, Wolmark N. Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial. J Clin Oncol. 2021;39(21):2367-2374. PMCID: PMC8462554.. PubMed PMID: 33739848; PMCID: PMC8462554.
Colen RR, Rolfo C, Ak M, Ayoub M, Ahmed S, Elshafeey N, Mamindla P, Zinn PO, Ng C, Vikram R, Bakas S, Peterson CB, Rodon Ahnert J, Subbiah V, Karp DD, Stephen B, Hajjar J, Naing A. Author response to Cunha et al. J Immunother Cancer. 2021-07-01;9(7): doi: 10.1136/jitc-2021-003299. nihFormattedCitation: Colen RR, Rolfo C, Ak M, Ayoub M, Ahmed S, Elshafeey N, Mamindla P, Zinn PO, Ng C, Vikram R, Bakas S, Peterson CB, Rodon Ahnert J, Subbiah V, Karp DD, Stephen B, Hajjar J, Naing A. Author response to Cunha et al. J Immunother Cancer. 2021;9(7). PMCID: PMC8317086.. PubMed PMID: 34315823; PMCID: PMC8317086.
Namburi S, Broxmeyer HE, Hong CS, Whiteside TL, Boyiadzis M. DPP4(+) exosomes in AML patients' plasma suppress proliferation of hematopoietic progenitor cells. Leukemia. 2021-07-01;35(7):1925-1932. doi: 10.1038/s41375-020-01047-7. nihFormattedCitation: Namburi S, Broxmeyer HE, Hong CS, Whiteside TL, Boyiadzis M. DPP4(+) exosomes in AML patients' plasma suppress proliferation of hematopoietic progenitor cells. Leukemia. 2021;35(7):1925-1932. PMCID: PMC10165724.. PubMed PMID: 33139859; PMCID: PMC10165724.
Xu P, Xi Y, Zhu J, Zhang M, Luka Z, Stolz DB, Cai X, Xie Y, Xu M, Ren S, Huang Z, Yang D, York JD, Ma X, Xie W. Intestinal Sulfation Is Essential to Protect Against Colitis and Colonic Carcinogenesis. Gastroenterology. 2021-07-01;161(1):271-286.e11. doi: 10.1053/j.gastro.2021.03.048. nihFormattedCitation: Xu P, Xi Y, Zhu J, Zhang M, Luka Z, Stolz DB, Cai X, Xie Y, Xu M, Ren S, Huang Z, Yang D, York JD, Ma X, Xie W. Intestinal Sulfation Is Essential to Protect Against Colitis and Colonic Carcinogenesis. Gastroenterology. 2021;161(1):271-286.e11. PMCID: PMC8238844.. PubMed PMID: 33819483; PMCID: PMC8238844.
Bender CM, Sereika SM, Gentry AL, Duquette JE, Casillo FE, Marsland A, Brufsky AM, Evans S, Gorantla VC, Grahovac TL, McAuliffe PF, Steiman JG, Zhu Y, Erickson KI. Physical activity, cardiorespiratory fitness, and cognitive function in postmenopausal women with breast cancer. Support Care Cancer. 2021-07-01;29(7):3743-3752. doi: 10.1007/s00520-020-05865-4. nihFormattedCitation: Bender CM, Sereika SM, Gentry AL, Duquette JE, Casillo FE, Marsland A, Brufsky AM, Evans S, Gorantla VC, Grahovac TL, McAuliffe PF, Steiman JG, Zhu Y, Erickson KI. Physical activity, cardiorespiratory fitness, and cognitive function in postmenopausal women with breast cancer. Support Care Cancer. 2021;29(7):3743-3752. PMCID: PMC8131400.. PubMed PMID: 33210238; PMCID: PMC8131400.
Olawaiye AB, Baker TP, Washington MK, Mutch DG. The new (Version 9) American Joint Committee on Cancer tumor, node, metastasis staging for cervical cancer. CA Cancer J Clin. 2021-07-01;71(4):287-298. doi: 10.3322/caac.21663. nihFormattedCitation: Olawaiye AB, Baker TP, Washington MK, Mutch DG. The new (Version 9) American Joint Committee on Cancer tumor, node, metastasis staging for cervical cancer. CA Cancer J Clin. 2021;71(4):287-298.. PubMed PMID: 33784415.
Camidge DR, Otterson GA, Clark JW, Ignatius Ou SH, Weiss J, Ades S, Shapiro GI, Socinski MA, Murphy DA, Conte U, Tang Y, Wang SC, Wilner KD, Villaruz LC. Crizotinib in Patients With MET-Amplified NSCLC. J Thorac Oncol. 2021-06-01;16(6):1017-1029. doi: 10.1016/j.jtho.2021.02.010. nihFormattedCitation: Camidge DR, Otterson GA, Clark JW, Ignatius Ou SH, Weiss J, Ades S, Shapiro GI, Socinski MA, Murphy DA, Conte U, Tang Y, Wang SC, Wilner KD, Villaruz LC. Crizotinib in Patients With MET-Amplified NSCLC. J Thorac Oncol. 2021;16(6):1017-1029.. PubMed PMID: 33676017.
Zureikat AH, Beane JD, Zenati MS, Al Abbas AI, Boone BA, Moser AJ, Bartlett DL, Hogg ME, Zeh HJ 3rd. 500 Minimally Invasive Robotic Pancreatoduodenectomies: One Decade of Optimizing Performance. Ann Surg. 2021-05-01;273(5):966-972. doi: 10.1097/SLA.0000000000003550. nihFormattedCitation: Zureikat AH, Beane JD, Zenati MS, Al Abbas AI, Boone BA, Moser AJ, Bartlett DL, Hogg ME, Zeh HJ 3rd. 500 Minimally Invasive Robotic Pancreatoduodenectomies: One Decade of Optimizing Performance. Ann Surg. 2021;273(5):966-972. PMCID: PMC7871451.. PubMed PMID: 31851003; PMCID: PMC7871451.
Johnston SRD, Harbeck N, Toi M, Martin M, O'Shaughnessy J, Rastogi P. Reply to K. Hashimoto and A. Shimomura. J Clin Oncol. 2021-05-01;39(13):1507-1508. doi: 10.1200/JCO.20.03477. nihFormattedCitation: Johnston SRD, Harbeck N, Toi M, Martin M, O'Shaughnessy J, Rastogi P. Reply to K. Hashimoto and A. Shimomura. J Clin Oncol. 2021;39(13):1507-1508.. PubMed PMID: 33630658.
Gough A, Soto-Gutierrez A, Vernetti L, Ebrahimkhani MR, Stern AM, Taylor DL. Human biomimetic liver microphysiology systems in drug development and precision medicine. Nat Rev Gastroenterol Hepatol. 2021-04-01;18(4):252-268. doi: 10.1038/s41575-020-00386-1. nihFormattedCitation: Gough A, Soto-Gutierrez A, Vernetti L, Ebrahimkhani MR, Stern AM, Taylor DL. Human biomimetic liver microphysiology systems in drug development and precision medicine. Nat Rev Gastroenterol Hepatol. 2021;18(4):252-268. PMCID: PMC9106093.. PubMed PMID: 33335282; PMCID: PMC9106093.
Lontos K, Yabes JG, Farah RJ, Boyiadzis M. Impact of upfront chemotherapy on overall survival in isolated myeloid sarcoma. Leukemia. 2021-04-01;35(4):1193-1196. doi: 10.1038/s41375-020-01017-z. nihFormattedCitation: Lontos K, Yabes JG, Farah RJ, Boyiadzis M. Impact of upfront chemotherapy on overall survival in isolated myeloid sarcoma. Leukemia. 2021;35(4):1193-1196.. PubMed PMID: 32814841.
Carleton N, Zou J, Fang Y, Koscumb SE, Shah OS, Chen F, Beriwal S, Diego EJ, Brufsky AM, Oesterreich S, Shapiro SD, Ferris R, Emens LA, Tseng G, Marroquin OC, Lee AV, McAuliffe PF. Outcomes After Sentinel Lymph Node Biopsy and Radiotherapy in Older Women With Early-Stage, Estrogen Receptor-Positive Breast Cancer. JAMA Netw Open. 2021-04-01;4(4):e216322. doi: 10.1001/jamanetworkopen.2021.6322. nihFormattedCitation: Carleton N, Zou J, Fang Y, Koscumb SE, Shah OS, Chen F, Beriwal S, Diego EJ, Brufsky AM, Oesterreich S, Shapiro SD, Ferris R, Emens LA, Tseng G, Marroquin OC, Lee AV, McAuliffe PF. Outcomes After Sentinel Lymph Node Biopsy and Radiotherapy in Older Women With Early-Stage, Estrogen Receptor-Positive Breast Cancer. JAMA Netw Open. 2021;4(4):e216322. PMCID: PMC8050744.. PubMed PMID: 33856473; PMCID: PMC8050744.
Colen RR, Rolfo C, Ak M, Ayoub M, Ahmed S, Elshafeey N, Mamindla P, Zinn PO, Ng C, Vikram R, Bakas S, Peterson CB, Rodon Ahnert J, Subbiah V, Karp DD, Stephen B, Hajjar J, Naing A. Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. J Immunother Cancer. 2021-04-01;9(4): doi: 10.1136/jitc-2020-001752. nihFormattedCitation: Colen RR, Rolfo C, Ak M, Ayoub M, Ahmed S, Elshafeey N, Mamindla P, Zinn PO, Ng C, Vikram R, Bakas S, Peterson CB, Rodon Ahnert J, Subbiah V, Karp DD, Stephen B, Hajjar J, Naing A. Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. J Immunother Cancer. 2021;9(4). PMCID: PMC8051405.. PubMed PMID: 33849924; PMCID: PMC8051405.
Huang H, Huang Y, Chen Y, Luo Z, Zhang Z, Sun R, Wan Z, Sun J, Lu B, Zhang L, Hu J, Li S. A novel immunochemotherapy based on targeting of cyclooxygenase and induction of immunogenic cell death. Biomaterials. 2021-03-01;270120708. doi: 10.1016/j.biomaterials.2021.120708. nihFormattedCitation: Huang H, Huang Y, Chen Y, Luo Z, Zhang Z, Sun R, Wan Z, Sun J, Lu B, Zhang L, Hu J, Li S. A novel immunochemotherapy based on targeting of cyclooxygenase and induction of immunogenic cell death. Biomaterials. 2021;270:120708. PMCID: PMC7910750.. PubMed PMID: 33578254; PMCID: PMC7910750.
Sun J, Wan Z, Xu J, Luo Z, Ren P, Zhang B, Diao D, Huang Y, Li S. Tumor size-dependent abscopal effect of polydopamine-coated all-in-one nanoparticles for immunochemo-photothermal therapy of early- and late-stage metastatic cancer. Biomaterials. 2021-02-01;269120629. doi: 10.1016/j.biomaterials.2020.120629. nihFormattedCitation: Sun J, Wan Z, Xu J, Luo Z, Ren P, Zhang B, Diao D, Huang Y, Li S. Tumor size-dependent abscopal effect of polydopamine-coated all-in-one nanoparticles for immunochemo-photothermal therapy of early- and late-stage metastatic cancer. Biomaterials. 2021;269:120629. PMCID: PMC8466812.. PubMed PMID: 33387938; PMCID: PMC8466812.
Darrah K, Deiters A. Targeted Drug Delivery through Optical Control of Cell Lysis. ACS Cent Sci. 2021-01-27;7(1):11-13. doi: 10.1021/acscentsci.0c01562. nihFormattedCitation: Darrah K, Deiters A. Targeted Drug Delivery through Optical Control of Cell Lysis. ACS Cent Sci. 2021;7(1):11-13. PMCID: PMC7844846.. PubMed PMID: 33532563; PMCID: PMC7844846.
Saura C, Oliveira M, Kim SB, Yau T, Takano T, Brufsky A. Reply to T. J. A. Dekker, D.-C. Mo et al, and A. Seidman et al. J Clin Oncol. 2021-01-20;39(3):254-255. doi: 10.1200/JCO.20.02963. nihFormattedCitation: Saura C, Oliveira M, Kim SB, Yau T, Takano T, Brufsky A. Reply to T. J. A. Dekker, D.-C. Mo et al, and A. Seidman et al. J Clin Oncol. 2021;39(3):254-255.. PubMed PMID: 33332192.
Appleman LJ. Multifactorial, Biomarker-Based Predictive Models for Immunotherapy Response Enter the Arena. J Natl Cancer Inst. 2021-01-04;113(1):7-8. doi: 10.1093/jnci/djaa077. nihFormattedCitation: Appleman LJ. Multifactorial, Biomarker-Based Predictive Models for Immunotherapy Response Enter the Arena. J Natl Cancer Inst. 2021;113(1):7-8. PMCID: PMC7781442.. PubMed PMID: 32516413; PMCID: PMC7781442.
Ling DC, Moppins BL, Champ CE, Gorantla VC, Beriwal S. Quality of Regional Nodal Irradiation Plans in Breast Cancer Patients Across a Large Network-Can We Translate Results From Randomized Trials Into the Clinic? Pract Radiat Oncol. 2021-01-01;11(1):e30-e35. doi: 10.1016/j.prro.2020.06.007. nihFormattedCitation: Ling DC, Moppins BL, Champ CE, Gorantla VC, Beriwal S. Quality of Regional Nodal Irradiation Plans in Breast Cancer Patients Across a Large Network-Can We Translate Results From Randomized Trials Into the Clinic? Pract Radiat Oncol. 2021;11(1):e30-e35.. PubMed PMID: 32615162.
Pham D, Deter CJ, Reinard MC, Gibson GA, Kiselyov K, Yu W, Sandulache VC, St Croix CM, Koide K. Using Ligand-Accelerated Catalysis to Repurpose Fluorogenic Reactions for Platinum or Copper. ACS Cent Sci. 2020-10-28;6(10):1772-1788. doi: 10.1021/acscentsci.0c00676. nihFormattedCitation: Pham D, Deter CJ, Reinard MC, Gibson GA, Kiselyov K, Yu W, Sandulache VC, St Croix CM, Koide K. Using Ligand-Accelerated Catalysis to Repurpose Fluorogenic Reactions for Platinum or Copper. ACS Cent Sci. 2020;6(10):1772-1788. PMCID: PMC7596870.. PubMed PMID: 33145414; PMCID: PMC7596870.
Fang Z, Wang Y, Wang Z, Xu M, Ren S, Yang D, Hong M, Xie W. ERINA Is an Estrogen-Responsive LncRNA That Drives Breast Cancer through the E2F1/RB1 Pathway. Cancer Res. 2020-10-15;80(20):4399-4413. doi: 10.1158/0008-5472.CAN-20-1031. nihFormattedCitation: Fang Z, Wang Y, Wang Z, Xu M, Ren S, Yang D, Hong M, Xie W. ERINA Is an Estrogen-Responsive LncRNA That Drives Breast Cancer through the E2F1/RB1 Pathway. Cancer Res. 2020;80(20):4399-4413. PMCID: PMC7572695.. PubMed PMID: 32826278; PMCID: PMC7572695.
Boyiadzis MM, Aksentijevich I, Arber DA, Barrett J, Brentjens RJ, Brufsky J, Cortes J, De Lima M, Forman SJ, Fuchs EJ, Fukas LJ, Gore SD, Litzow MR, Miller JS, Pagel JM, Waller EK, Tallman MS. The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. J Immunother Cancer. 2020-10-01;8(2): doi: 10.1136/jitc-2020-000810. nihFormattedCitation: Boyiadzis MM, Aksentijevich I, Arber DA, Barrett J, Brentjens RJ, Brufsky J, Cortes J, De Lima M, Forman SJ, Fuchs EJ, Fukas LJ, Gore SD, Litzow MR, Miller JS, Pagel JM, Waller EK, Tallman MS. The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. J Immunother Cancer. 2020;8(2). PMCID: PMC7574947.. PubMed PMID: 33077513; PMCID: PMC7574947.
Pham D, Basu U, Pohorilets I, St Croix CM, Watkins SC, Koide K. Fluorogenic Probe Using a Mislow-Evans Rearrangement for Real-Time Imaging of Hydrogen Peroxide. Angew Chem Int Ed Engl. 2020-09-28;59(40):17435-17441. doi: 10.1002/anie.202007104. nihFormattedCitation: Pham D, Basu U, Pohorilets I, St Croix CM, Watkins SC, Koide K. Fluorogenic Probe Using a Mislow-Evans Rearrangement for Real-Time Imaging of Hydrogen Peroxide. Angew Chem Int Ed Engl. 2020;59(40):17435-17441.. PubMed PMID: 32585075.
Swain SM, Tang G, Brauer HA, Goerlitz DS, Lucas PC, Robidoux A, Harris BT, Bandos H, Ren Y, Geyer CE Jr, Rastogi P, Mamounas EP, Wolmark N. NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response. Clin Cancer Res. 2020-08-15;26(16):4233-4241. doi: 10.1158/1078-0432.CCR-20-0152. nihFormattedCitation: Swain SM, Tang G, Brauer HA, Goerlitz DS, Lucas PC, Robidoux A, Harris BT, Bandos H, Ren Y, Geyer CE Jr, Rastogi P, Mamounas EP, Wolmark N. NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response. Clin Cancer Res. 2020;26(16):4233-4241. PMCID: PMC7724952.. PubMed PMID: 32371537; PMCID: PMC7724952.
Brufsky A, Mathew A. Bisphosphonate Choice as Adjuvant Therapy for Breast Cancer: Does it Matter? J Natl Cancer Inst. 2020-07-01;112(7):659-660. doi: 10.1093/jnci/djz216. nihFormattedCitation: Brufsky A, Mathew A. Bisphosphonate Choice as Adjuvant Therapy for Breast Cancer: Does it Matter? J Natl Cancer Inst. 2020;112(7):659-660. PMCID: PMC7357314.. PubMed PMID: 31693134; PMCID: PMC7357314.
Silva Barbosa AC, Zhou D, Xie Y, Choi YJ, Tung HC, Chen X, Xu M, Gibbs RB, Poloyac SM, Liu S, Yu Y, Luo J, Liu Y, Xie W. Inhibition of Estrogen Sulfotransferase (SULT1E1/EST) Ameliorates Ischemic Acute Kidney Injury in Mice. J Am Soc Nephrol. 2020-07-01;31(7):1496-1508. doi: 10.1681/ASN.2019080767. nihFormattedCitation: Silva Barbosa AC, Zhou D, Xie Y, Choi YJ, Tung HC, Chen X, Xu M, Gibbs RB, Poloyac SM, Liu S, Yu Y, Luo J, Liu Y, Xie W. Inhibition of Estrogen Sulfotransferase (SULT1E1/EST) Ameliorates Ischemic Acute Kidney Injury in Mice. J Am Soc Nephrol. 2020;31(7):1496-1508. PMCID: PMC7351010.. PubMed PMID: 32424001; PMCID: PMC7351010.
Zhou W, Brown W, Bardhan A, Delaney M, Ilk AS, Rauen RR, Kahn SI, Tsang M, Deiters A. Spatiotemporal Control of CRISPR/Cas9 Function in Cells and Zebrafish using Light-Activated Guide RNA. Angew Chem Int Ed Engl. 2020-06-02;59(23):8998-9003. doi: 10.1002/anie.201914575. nihFormattedCitation: Zhou W, Brown W, Bardhan A, Delaney M, Ilk AS, Rauen RR, Kahn SI, Tsang M, Deiters A. Spatiotemporal Control of CRISPR/Cas9 Function in Cells and Zebrafish using Light-Activated Guide RNA. Angew Chem Int Ed Engl. 2020;59(23):8998-9003. PMCID: PMC7250724.. PubMed PMID: 32160370; PMCID: PMC7250724.
Somasundaram A, Socinski MA, Villaruz LC. Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer. Drugs. 2020-06-01;80(9):883-892. doi: 10.1007/s40265-020-01320-0. nihFormattedCitation: Somasundaram A, Socinski MA, Villaruz LC. Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer. Drugs. 2020;80(9):883-892. PMCID: PMC8579493.. PubMed PMID: 32436070; PMCID: PMC8579493.
Sun J, Wan Z, Chen Y, Xu J, Luo Z, Parise RA, Diao D, Ren P, Beumer JH, Lu B, Li S. Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy. Acta Biomater. 2020-04-01;106289-300. doi: 10.1016/j.actbio.2020.01.039. nihFormattedCitation: Sun J, Wan Z, Chen Y, Xu J, Luo Z, Parise RA, Diao D, Ren P, Beumer JH, Lu B, Li S. Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy. Acta Biomater. 2020;106:289-300. PMCID: PMC7183357.. PubMed PMID: 32004652; PMCID: PMC7183357.
Luo Z, Xu J, Sun J, Huang H, Zhang Z, Ma W, Wan Z, Liu Y, Pardeshi A, Li S. Co-delivery of 2-Deoxyglucose and a glutamine metabolism inhibitor V9302 via a prodrug micellar formulation for synergistic targeting of metabolism in cancer. Acta Biomater. 2020-03-15;105239-252. doi: 10.1016/j.actbio.2020.01.019. nihFormattedCitation: Luo Z, Xu J, Sun J, Huang H, Zhang Z, Ma W, Wan Z, Liu Y, Pardeshi A, Li S. Co-delivery of 2-Deoxyglucose and a glutamine metabolism inhibitor V9302 via a prodrug micellar formulation for synergistic targeting of metabolism in cancer. Acta Biomater. 2020;105:239-252. PMCID: PMC7105957.. PubMed PMID: 31958597; PMCID: PMC7105957.
Nasrazadani A, Brufsky AM. Capivasertib inhibits a key pathway in metastatic breast cancer. Lancet Oncol. 2020-03-01;21(3):318-319. doi: 10.1016/S1470-2045(19)30857-5. nihFormattedCitation: Nasrazadani A, Brufsky AM. Capivasertib inhibits a key pathway in metastatic breast cancer. Lancet Oncol. 2020;21(3):318-319.. PubMed PMID: 32035019.
Fehrenbacher L, Cecchini RS, Geyer CE Jr, Rastogi P, Costantino JP, Atkins JN, Crown JP, Polikoff J, Boileau JF, Provencher L, Stokoe C, Moore TD, Robidoux A, Flynn PJ, Borges VF, Albain KS, Swain SM, Paik S, Mamounas EP, Wolmark N. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. J Clin Oncol. 2020-02-10;38(5):444-453. doi: 10.1200/JCO.19.01455. nihFormattedCitation: Fehrenbacher L, Cecchini RS, Geyer CE Jr, Rastogi P, Costantino JP, Atkins JN, Crown JP, Polikoff J, Boileau JF, Provencher L, Stokoe C, Moore TD, Robidoux A, Flynn PJ, Borges VF, Albain KS, Swain SM, Paik S, Mamounas EP, Wolmark N. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. J Clin Oncol. 2020;38(5):444-453. PMCID: PMC7007289.. PubMed PMID: 31821109; PMCID: PMC7007289.
Naro Y, Darrah K, Deiters A. Optical Control of Small Molecule-Induced Protein Degradation. J Am Chem Soc. 2020-02-05;142(5):2193-2197. doi: 10.1021/jacs.9b12718. nihFormattedCitation: Naro Y, Darrah K, Deiters A. Optical Control of Small Molecule-Induced Protein Degradation. J Am Chem Soc. 2020;142(5):2193-2197. PMCID: PMC7229639.. PubMed PMID: 31927988; PMCID: PMC7229639.
Ma W, Sun J, Xu J, Luo Z, Diao D, Zhang Z, Oberly PJ, Minnigh MB, Xie W, Poloyac SM, Huang Y, Li S. Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier. Theranostics. 2020-01-20;10(6):2463-2478. doi: 10.7150/thno.38973. nihFormattedCitation: Ma W, Sun J, Xu J, Luo Z, Diao D, Zhang Z, Oberly PJ, Minnigh MB, Xie W, Poloyac SM, Huang Y, Li S. Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier. Theranostics. 2020;10(6):2463-2478. PMCID: PMC7052901.. PubMed PMID: 32194813; PMCID: PMC7052901.
Xie W. Editorial of Special Issue on Drug Metabolism and Disposition in Diseases. Acta Pharm Sin B. 2020-01-01;10(1):2. doi: 10.1016/j.apsb.2019.12.016. nihFormattedCitation: Xie W. Editorial of Special Issue on Drug Metabolism and Disposition in Diseases. Acta Pharm Sin B. 2020;10(1):2. PMCID: PMC6977160.. PubMed PMID: 31993303; PMCID: PMC6977160.
Sun J, Chen Y, Xu J, Song X, Wan Z, Du Y, Ma W, Li X, Zhang L, Li S. High Loading of Hydrophobic and Hydrophilic Agents via Small Immunostimulatory Carrier for Enhanced Tumor Penetration and Combinational Therapy. Theranostics. 2020-01-01;10(3):1136-1150. doi: 10.7150/thno.38287. nihFormattedCitation: Sun J, Chen Y, Xu J, Song X, Wan Z, Du Y, Ma W, Li X, Zhang L, Li S. High Loading of Hydrophobic and Hydrophilic Agents via Small Immunostimulatory Carrier for Enhanced Tumor Penetration and Combinational Therapy. Theranostics. 2020;10(3):1136-1150. PMCID: PMC6956803.. PubMed PMID: 31938056; PMCID: PMC6956803.
Wang Y, Fang Z, Hong M, Yang D, Xie W. Long-noncoding RNAs (lncRNAs) in drug metabolism and disposition, implications in cancer chemo-resistance. Acta Pharm Sin B. 2020-01-01;10(1):105-112. doi: 10.1016/j.apsb.2019.09.011. nihFormattedCitation: Wang Y, Fang Z, Hong M, Yang D, Xie W. Long-noncoding RNAs (lncRNAs) in drug metabolism and disposition, implications in cancer chemo-resistance. Acta Pharm Sin B. 2020;10(1):105-112. PMCID: PMC6976993.. PubMed PMID: 31993309; PMCID: PMC6976993.
Vicini FA, Cecchini RS, White JR, Arthur DW, Julian TB, Rabinovitch RA, Kuske RR, Ganz PA, Parda DS, Scheier MF, Winter KA, Paik S, Kuerer HM, Vallow LA, Pierce LJ, Mamounas EP, McCormick B, Costantino JP, Bear HD, Germain I, Gustafson G, Grossheim L, Petersen IA, Hudes RS, Curran WJ Jr, Bryant JL, Wolmark N. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet. 2019-12-14;394(10215):2155-2164. doi: 10.1016/S0140-6736(19)32514-0. nihFormattedCitation: Vicini FA, Cecchini RS, White JR, Arthur DW, Julian TB, Rabinovitch RA, Kuske RR, Ganz PA, Parda DS, Scheier MF, Winter KA, Paik S, Kuerer HM, Vallow LA, Pierce LJ, Mamounas EP, McCormick B, Costantino JP, Bear HD, Germain I, Gustafson G, Grossheim L, Petersen IA, Hudes RS, Curran WJ Jr, Bryant JL, Wolmark N. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet. 2019;394(10215):2155-2164. PMCID: PMC7199428.. PubMed PMID: 31813636; PMCID: PMC7199428.
Nasrazadani A, Brufsky AM. CDK4/6 inhibitors: taking the place of chemotherapy? Lancet Oncol. 2019-10-01;20(10):1329-1330. doi: 10.1016/S1470-2045(19)30507-8. nihFormattedCitation: Nasrazadani A, Brufsky AM. CDK4/6 inhibitors: taking the place of chemotherapy? Lancet Oncol. 2019;20(10):1329-1330.. PubMed PMID: 31494036.
Duvvuri U, George J, Kim S, Alvarado D, Neumeister VM, Chenna A, Gedrich R, Hawthorne T, LaVallee T, Grandis JR, Bauman JE. Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients. Clin Cancer Res. 2019-10-01;25(19):5752-5758. doi: 10.1158/1078-0432.CCR-18-3453. nihFormattedCitation: Duvvuri U, George J, Kim S, Alvarado D, Neumeister VM, Chenna A, Gedrich R, Hawthorne T, LaVallee T, Grandis JR, Bauman JE. Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients. Clin Cancer Res. 2019;25(19):5752-5758. PMCID: PMC6820348.. PubMed PMID: 31308059; PMCID: PMC6820348.
Courtney TM, Deiters A. Optical control of protein phosphatase function. Nat Commun. 2019-09-26;10(1):4384. doi: 10.1038/s41467-019-12260-z. nihFormattedCitation: Courtney TM, Deiters A. Optical control of protein phosphatase function. Nat Commun. 2019;10(1):4384. PMCID: PMC6763421.. PubMed PMID: 31558717; PMCID: PMC6763421.
Xie Y, Xu M, Deng M, Li Z, Wang P, Ren S, Guo Y, Ma X, Fan J, Billiar TR, Xie W. Activation of Pregnane X Receptor Sensitizes Mice to Hemorrhagic Shock-Induced Liver Injury. Hepatology. 2019-09-01;70(3):995-1010. doi: 10.1002/hep.30691. nihFormattedCitation: Xie Y, Xu M, Deng M, Li Z, Wang P, Ren S, Guo Y, Ma X, Fan J, Billiar TR, Xie W. Activation of Pregnane X Receptor Sensitizes Mice to Hemorrhagic Shock-Induced Liver Injury. Hepatology. 2019;70(3):995-1010. PMCID: PMC6717545.. PubMed PMID: 31038762; PMCID: PMC6717545.
Yan J, Tung HC, Li S, Niu Y, Garbacz WG, Lu P, Bi Y, Li Y, He J, Xu M, Ren S, Monga SP, Schwabe RF, Yang D, Xie W. Aryl Hydrocarbon Receptor Signaling Prevents Activation of Hepatic Stellate Cells and Liver Fibrogenesis in Mice. Gastroenterology. 2019-09-01;157(3):793-806.e14. doi: 10.1053/j.gastro.2019.05.066. nihFormattedCitation: Yan J, Tung HC, Li S, Niu Y, Garbacz WG, Lu P, Bi Y, Li Y, He J, Xu M, Ren S, Monga SP, Schwabe RF, Yang D, Xie W. Aryl Hydrocarbon Receptor Signaling Prevents Activation of Hepatic Stellate Cells and Liver Fibrogenesis in Mice. Gastroenterology. 2019;157(3):793-806.e14. PMCID: PMC6707837.. PubMed PMID: 31170413; PMCID: PMC6707837.
Nasrazadani A, Brufsky AM. Artificial intelligence-directed prognostication of breast cancer. EBioMedicine. 2019-08-01;466-7. doi: 10.1016/j.ebiom.2019.07.073. nihFormattedCitation: Nasrazadani A, Brufsky AM. Artificial intelligence-directed prognostication of breast cancer. EBioMedicine. 2019;46:6-7. PMCID: PMC6712046.. PubMed PMID: 31378696; PMCID: PMC6712046.
Elshafeey N, Kotrotsou A, Hassan A, Elshafei N, Hassan I, Ahmed S, Abrol S, Agarwal A, El Salek K, Bergamaschi S, Acharya J, Moron FE, Law M, Fuller GN, Huse JT, Zinn PO, Colen RR. Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma. Nat Commun. 2019-07-18;10(1):3170. doi: 10.1038/s41467-019-11007-0. nihFormattedCitation: Elshafeey N, Kotrotsou A, Hassan A, Elshafei N, Hassan I, Ahmed S, Abrol S, Agarwal A, El Salek K, Bergamaschi S, Acharya J, Moron FE, Law M, Fuller GN, Huse JT, Zinn PO, Colen RR. Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma. Nat Commun. 2019;10(1):3170. PMCID: PMC6639324.. PubMed PMID: 31320621; PMCID: PMC6639324.
Xu J, Sun J, Ho PY, Luo Z, Ma W, Zhao W, Rathod SB, Fernandez CA, Venkataramanan R, Xie W, Yu AM, Li S. Creatine based polymer for codelivery of bioengineered MicroRNA and chemodrugs against breast cancer lung metastasis. Biomaterials. 2019-07-01;21025-40. doi: 10.1016/j.biomaterials.2019.04.025. nihFormattedCitation: Xu J, Sun J, Ho PY, Luo Z, Ma W, Zhao W, Rathod SB, Fernandez CA, Venkataramanan R, Xie W, Yu AM, Li S. Creatine based polymer for codelivery of bioengineered MicroRNA and chemodrugs against breast cancer lung metastasis. Biomaterials. 2019;210:25-40. PMCID: PMC6538300.. PubMed PMID: 31054369; PMCID: PMC6538300.
Singhi AD, George B, Greenbowe JR, Chung J, Suh J, Maitra A, Klempner SJ, Hendifar A, Milind JM, Golan T, Brand RE, Zureikat AH, Roy S, Schrock AB, Miller VA, Ross JS, Ali SM, Bahary N. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. Gastroenterology. 2019-06-01;156(8):2242-2253.e4. doi: 10.1053/j.gastro.2019.02.037. nihFormattedCitation: Singhi AD, George B, Greenbowe JR, Chung J, Suh J, Maitra A, Klempner SJ, Hendifar A, Milind JM, Golan T, Brand RE, Zureikat AH, Roy S, Schrock AB, Miller VA, Ross JS, Ali SM, Bahary N. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. Gastroenterology. 2019;156(8):2242-2253.e4.. PubMed PMID: 30836094.
Wan Z, Sun J, Xu J, Moharil P, Chen J, Xu J, Zhu J, Li J, Huang Y, Xu P, Ma X, Xie W, Lu B, Li S. Dual functional immunostimulatory polymeric prodrug carrier with pendent indoximod for enhanced cancer immunochemotherapy. Acta Biomater. 2019-05-01;90300-313. doi: 10.1016/j.actbio.2019.03.048. nihFormattedCitation: Wan Z, Sun J, Xu J, Moharil P, Chen J, Xu J, Zhu J, Li J, Huang Y, Xu P, Ma X, Xie W, Lu B, Li S. Dual functional immunostimulatory polymeric prodrug carrier with pendent indoximod for enhanced cancer immunochemotherapy. Acta Biomater. 2019;90:300-313. PMCID: PMC6513707.. PubMed PMID: 30930305; PMCID: PMC6513707.
Bhatla N, Berek JS, Cuello Fredes M, Denny LA, Grenman S, Karunaratne K, Kehoe ST, Konishi I, Olawaiye AB, Prat J, Sankaranarayanan R, Brierley J, Mutch D, Querleu D, Cibula D, Quinn M, Botha H, Sigurd L, Rice L, Ryu HS, Ngan H, Mäenpää J, Andrijono A, Purwoto G, Maheshwari A, Bafna UD, Plante M, Natarajan J. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2019-04-01;145(1):129-135. doi: 10.1002/ijgo.12749. nihFormattedCitation: Bhatla N, Berek JS, Cuello Fredes M, Denny LA, Grenman S, Karunaratne K, Kehoe ST, Konishi I, Olawaiye AB, Prat J, Sankaranarayanan R, Brierley J, Mutch D, Querleu D, Cibula D, Quinn M, Botha H, Sigurd L, Rice L, Ryu HS, Ngan H, Mäenpää J, Andrijono A, Purwoto G, Maheshwari A, Bafna UD, Plante M, Natarajan J. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2019;145(1):129-135.. PubMed PMID: 30656645.
Clump DA, Pickering CR, Skinner HD. Predicting Outcome in Head and Neck Cancer: miRNAs with Potentially Big Effects. Clin Cancer Res. 2019-03-01;25(5):1441-1442. doi: 10.1158/1078-0432.CCR-18-3078. nihFormattedCitation: Clump DA, Pickering CR, Skinner HD. Predicting Outcome in Head and Neck Cancer: miRNAs with Potentially Big Effects. Clin Cancer Res. 2019;25(5):1441-1442. PMCID: PMC6415532.. PubMed PMID: 30413524; PMCID: PMC6415532.
Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV, Porter DL, Maloney DG, Grupp SA, Mackall CL, June CH, Bishop MR. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer. 2018-12-04;6(1):137. doi: 10.1186/s40425-018-0460-5. nihFormattedCitation: Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV, Porter DL, Maloney DG, Grupp SA, Mackall CL, June CH, Bishop MR. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer. 2018;6(1):137. PMCID: PMC6278156.. PubMed PMID: 30514386; PMCID: PMC6278156.
Guo GL, Xie W. Metformin action through the microbiome and bile acids. Nat Med. 2018-12-01;24(12):1789-1790. doi: 10.1038/s41591-018-0273-6. nihFormattedCitation: Guo GL, Xie W. Metformin action through the microbiome and bile acids. Nat Med. 2018;24(12):1789-1790.. PubMed PMID: 30523325.
Garcia CA, Dacic S, Villaruz LC. Disease Response with the Addition of Platinum-Based Chemotherapy to Pembrolizumab after Progression on Pembrolizumab Monotherapy in PD-L1-Expressing Non-Small Cell Lung Cancer. J Thorac Oncol. 2018-08-01;13(8):e135-e136. doi: 10.1016/j.jtho.2018.02.031. nihFormattedCitation: Garcia CA, Dacic S, Villaruz LC. Disease Response with the Addition of Platinum-Based Chemotherapy to Pembrolizumab after Progression on Pembrolizumab Monotherapy in PD-L1-Expressing Non-Small Cell Lung Cancer. J Thorac Oncol. 2018;13(8):e135-e136.. PubMed PMID: 30049372.
Sun J, Sun L, Li J, Xu J, Wan Z, Ouyang Z, Liang L, Li S, Zeng D. A multi-functional polymeric carrier for simultaneous positron emission tomography imaging and combination therapy. Acta Biomater. 2018-07-15;75312-322. doi: 10.1016/j.actbio.2018.06.010. nihFormattedCitation: Sun J, Sun L, Li J, Xu J, Wan Z, Ouyang Z, Liang L, Li S, Zeng D. A multi-functional polymeric carrier for simultaneous positron emission tomography imaging and combination therapy. Acta Biomater. 2018;75:312-322. PMCID: PMC6119490.. PubMed PMID: 29885530; PMCID: PMC6119490.
Boyiadzis MM, Kirkwood JM, Marshall JL, Pritchard CC, Azad NS, Gulley JL. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J Immunother Cancer. 2018-05-14;6(1):35. doi: 10.1186/s40425-018-0342-x. nihFormattedCitation: Boyiadzis MM, Kirkwood JM, Marshall JL, Pritchard CC, Azad NS, Gulley JL. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J Immunother Cancer. 2018;6(1):35. PMCID: PMC5950135.. PubMed PMID: 29754585; PMCID: PMC5950135.
Ankenbruck N, Courtney T, Naro Y, Deiters A. Optochemical Control of Biological Processes in Cells and Animals. Angew Chem Int Ed Engl. 2018-03-05;57(11):2768-2798. doi: 10.1002/anie.201700171. nihFormattedCitation: Ankenbruck N, Courtney T, Naro Y, Deiters A. Optochemical Control of Biological Processes in Cells and Animals. Angew Chem Int Ed Engl. 2018;57(11):2768-2798. PMCID: PMC6026863.. PubMed PMID: 28521066; PMCID: PMC6026863.
Lee DM, Duensing A. What's the FOX Got to Do with the KITten? Regulating the Lineage-Specific Transcriptional Landscape in GIST. Cancer Discov. 2018-02-01;8(2):146-149. doi: 10.1158/2159-8290.CD-17-1370. nihFormattedCitation: Lee DM, Duensing A. What's the FOX Got to Do with the KITten? Regulating the Lineage-Specific Transcriptional Landscape in GIST. Cancer Discov. 2018;8(2):146-149.. PubMed PMID: 29431674.
Branstetter BF 4th. The Future of Radiology. JAMA. 2017-12-05;318(21):2141. doi: 10.1001/jama.2017.16659. nihFormattedCitation: Branstetter BF 4th. The Future of Radiology. JAMA. 2017;318(21):2141.. PubMed PMID: 29209714.
Godse NR, Khan N, Yochum ZA, Gomez-Casal R, Kemp C, Shiwarski DJ, Seethala RS, Kulich S, Seshadri M, Burns TF, Duvvuri U. TMEM16A/ANO1 Inhibits Apoptosis Via Downregulation of Bim Expression. Clin Cancer Res. 2017-12-01;23(23):7324-7332. doi: 10.1158/1078-0432.CCR-17-1561. nihFormattedCitation: Godse NR, Khan N, Yochum ZA, Gomez-Casal R, Kemp C, Shiwarski DJ, Seethala RS, Kulich S, Seshadri M, Burns TF, Duvvuri U. TMEM16A/ANO1 Inhibits Apoptosis Via Downregulation of Bim Expression. Clin Cancer Res. 2017;23(23):7324-7332. PMCID: PMC5898434.. PubMed PMID: 28899969; PMCID: PMC5898434.
Morihiro K, Ankenbruck N, Lukasak B, Deiters A. Small Molecule Release and Activation through DNA Computing. J Am Chem Soc. 2017-10-04;139(39):13909-13915. doi: 10.1021/jacs.7b07831. nihFormattedCitation: Morihiro K, Ankenbruck N, Lukasak B, Deiters A. Small Molecule Release and Activation through DNA Computing. J Am Chem Soc. 2017;139(39):13909-13915.. PubMed PMID: 28945369.
Caritis SN, Bastian JR, Zhang H, Kalluri H, English D, England M, Bobby S, Venkataramanan R. An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy. Am J Obstet Gynecol. 2017-10-01;217(4):459.e1-459.e6. doi: 10.1016/j.ajog.2017.06.029. nihFormattedCitation: Caritis SN, Bastian JR, Zhang H, Kalluri H, English D, England M, Bobby S, Venkataramanan R. An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy. Am J Obstet Gynecol. 2017;217(4):459.e1-459.e6. PMCID: PMC5614874.. PubMed PMID: 28669739; PMCID: PMC5614874.
Brufsky AM. Long-term management of patients with hormone receptor-positive metastatic breast cancer: Concepts for sequential and combination endocrine-based therapies. Cancer Treat Rev. 2017-09-01;5922-32. doi: 10.1016/j.ctrv.2017.06.004. nihFormattedCitation: Brufsky AM. Long-term management of patients with hormone receptor-positive metastatic breast cancer: Concepts for sequential and combination endocrine-based therapies. Cancer Treat Rev. 2017;59:22-32.. PubMed PMID: 28719836.
Roy A, Ye J, Deng F, Wang QJ. Protein kinase D signaling in cancer: A friend or foe? Biochim Biophys Acta Rev Cancer. 2017-08-01;1868(1):283-294. doi: 10.1016/j.bbcan.2017.05.008. nihFormattedCitation: Roy A, Ye J, Deng F, Wang QJ. Protein kinase D signaling in cancer: A friend or foe? Biochim Biophys Acta Rev Cancer. 2017;1868(1):283-294. PMCID: PMC5548606.. PubMed PMID: 28577984; PMCID: PMC5548606.
Zhu Q, Liu X. Discovery of a Calcium-Dependent Enzymatic Cascade for the Selective Assembly of Hapalindole-Type Alkaloids: On the Biosynthetic Origin of Hapalindole U. Angew Chem Int Ed Engl. 2017-07-24;56(31):9062-9066. doi: 10.1002/anie.201703932. nihFormattedCitation: Zhu Q, Liu X. Discovery of a Calcium-Dependent Enzymatic Cascade for the Selective Assembly of Hapalindole-Type Alkaloids: On the Biosynthetic Origin of Hapalindole U. Angew Chem Int Ed Engl. 2017;56(31):9062-9066.. PubMed PMID: 28626997.
Liu J, Hemphill J, Samanta S, Tsang M, Deiters A. Genetic Code Expansion in Zebrafish Embryos and Its Application to Optical Control of Cell Signaling. J Am Chem Soc. 2017-07-12;139(27):9100-9103. doi: 10.1021/jacs.7b02145. nihFormattedCitation: Liu J, Hemphill J, Samanta S, Tsang M, Deiters A. Genetic Code Expansion in Zebrafish Embryos and Its Application to Optical Control of Cell Signaling. J Am Chem Soc. 2017;139(27):9100-9103. PMCID: PMC6022368.. PubMed PMID: 28657738; PMCID: PMC6022368.
Mathew A, Brufsky A. TACT2: improving treatment tolerability in early breast cancer. Lancet Oncol. 2017-07-01;18(7):843-845. doi: 10.1016/S1470-2045(17)30437-0. nihFormattedCitation: Mathew A, Brufsky A. TACT2: improving treatment tolerability in early breast cancer. Lancet Oncol. 2017;18(7):843-845.. PubMed PMID: 28677561.
Singhi AD, Ali SM, Lacy J, Hendifar A, Nguyen K, Koo J, Chung JH, Greenbowe J, Ross JS, Nikiforova MN, Zeh HJ, Sarkaria IS, Dasyam A, Bahary N. Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma. J Natl Compr Canc Netw. 2017-05-01;15(5):555-562. doi: 10.6004/jnccn.2017.0058. nihFormattedCitation: Singhi AD, Ali SM, Lacy J, Hendifar A, Nguyen K, Koo J, Chung JH, Greenbowe J, Ross JS, Nikiforova MN, Zeh HJ, Sarkaria IS, Dasyam A, Bahary N. Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma. J Natl Compr Canc Netw. 2017;15(5):555-562.. PubMed PMID: 28476735.
